ESRRA and metabolic dysfunction-associated steatotic liver disease: Based on the role of ERRα in directing hepatic VLDL-TG secretion, an important concern for these ERRα inverse agonists would be drug-induced NAFLD upon prolonged dosing; particularly, in females.